Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Kurt W. Tauer
No relevant relationships to disclose
Robert C. Hermann
Honoraria - Genentech
Research Funding - Eisai
Petros G. Nikolinakos
No relevant relationships to disclose
Arthur C. Houts
No relevant relationships to disclose